Latest news with #Fycompa
Yahoo
07-08-2025
- Business
- Yahoo
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks Consensus Estimate of 58 cents. The company had recorded adjusted earnings of 56 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $146.6 million in the reported quarter, representing growth of 19% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $139 million. Catalyst Pharmaceuticals' top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), and the epilepsy drug Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line. CPRX's Q1 Results in Detail Firdapse generated sales worth $84.8 million in the reported quarter, up 10% year over year, driven by organic sales growth. The reported figure, however, missed the Zacks Consensus Estimate of $88 million as well as our estimate of $87 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients. In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company's portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023. Fycompa generated net product revenues of $34.3 million, down 6% year over year, as tablet generics began hitting the market in late May following the expiry of the expiration of one of its patents. Oral suspension remains exclusive until mid-December 2025, but revenues are expected to decline with growing generic competition. The reported figure, however, surpassed the Zacks Consensus Estimate of $25.9 million as well as our model estimate of $26.7 million. Year to date, shares of CPRX have gained 4.4% compared with the industry's 5.9% growth. Image Source: Zacks Investment Research In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024. In the reported quarter, Agamree generated revenues worth $27.4 million, up significantly year over year. The reported figure beat the Zacks Consensus Estimate of $25.1 million and our estimate of $25.2 million. Research and development (R&D) expenses were $4.4 million in the reported quarter, up 46% year over year. Selling, general and administrative (SG&A) expenses totaled $45.9 million, up 13% year over year. As of June 30, 2025, Catalyst Pharmaceuticals had cash, cash equivalents and investments worth $652.8 million compared with $580.7 million as of March 31, 2025. CPRX Reaffirms 2025 Financial Guidance In 2025, Catalyst Pharmaceuticals continues to expect total revenues between $545 million and $565 million, reflecting continued growth in product revenues from Firdapse and Agamree. Firdapse revenues are expected between $355 million and $360 million. Agamree revenues are anticipated to be between $100 million and $110 million in the current year. Fycompa revenues are projected between $90 million and $95 million, which reflects the anticipated impact of the loss of market exclusivity of the drug in 2025. Catalyst Pharmaceuticals expects its R&D expenses to be between $15 million and $20 million in 2025 due to investments in the SUMMIT study evaluating the long-term efficacy and safety of Agamree over other DMD treatments. SG&A expenses are expected to rise steadily in 2025. Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Catalyst Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Catalyst Pharmaceuticals, Inc. Quote CPRX's Zacks Rank & Other Stocks to Consider Catalyst Pharmaceuticals currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Arvinas ARVN, CorMedix CRMD and Immunocore IMCR. While CRMD and IMCR sport a Zacks Rank #1 (Strong Buy) each at present, ARVN currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for CorMedix's earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 47.5%. CorMedix's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%. In the past 60 days, estimates for Immunocore's 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.8% year to date. Immunocore's earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%. In the past 60 days, estimates for Arvinas' 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 66.5% year to date. Arvinas' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report CorMedix Inc (CRMD) : Free Stock Analysis Report Arvinas, Inc. (ARVN) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Metro
09-07-2025
- Health
- Metro
All my son wanted was his prescription - the next day he died
Hopping out of the front passenger seat, I walked around the car to give my son, Charlie, a hug goodbye. It was June 26, 2021 and my husband, Richard, and I had just dropped him home. Charlie was looking forward to a relaxing night alone, eating takeaway and watching football. 'I love you,' I said. 'See you tomorrow for a Sunday roast?' He smiled, then walked off towards his flat. That was the last time I saw my son. Within just a few hours, Charlie was dead at 32. From a very early age, Charlie was always telling jokes and making people laugh. He was also a bit of a wind-up merchant to his four sisters, but we all loved him. At 14, he randomly started getting seizures. He didn't actually tell anyone except one of his friends at the time because he loved playing rugby, water polo, and cycling and he thought seizures could jeopardise that. Then it happened one day when he was at home. His sister, Lily, found him on his bedroom floor and ran down to tell me. We called for an ambulance and he was taken to Barnet Hospital, which is when I was devastated to find out from him that it had been going on for months. Within days, he was diagnosed with epilepsy. Over the years, Charlie tried at least 10 different types of medication to manage his condition, with little success. As a result, he'd have seizures monthly or even weekly, which resulted in broken noses or teeth, as well as split eyebrows and cheeks. More often than not, they came on randomly, which I know felt very frustrating for him. But some things like hot weather, exercise, or stress could induce them too. Then he started on a breakthrough drug called Fycompa that changed everything, aged 30. The seizures slowed right down and never really came on unprovoked anymore. He was finally in a good place. But it all came crumbling down in 2021. On Thursday June 24, Charlie received a notification that one of his recent contacts tested positive for Covid-19 so he needed to self-isolate. The problem was, he had planned to travel back to Brunel University of London – where he was studying occupational therapy – on Friday, which was two hours away. He was going to the campus pharmacy to pick up his repeat prescription, as he would run out of medication on Friday evening. But he could now no longer go due to travel restrictions. On Friday, Charlie contacted his GP to arrange an emergency refill, but this was never issued. By Friday, he had run out of medication and called me in a panic asking what to do. Calming him down, I suggested he call 111 because I'd received an urgent prescription from them before. Around 10:30am, he called and the operator told him they'd send it to his local pharmacy, Superdrug. Nervous that he'd be breaking Covid-19 rules about isolating, he asked if I'd come with him to pick it up. So Richard and I – as well as our grandchild, who we were babysitting at the time – got into a car and drove 20 minutes to meet him at the pharmacy. Richard and the baby stayed in the car, while I greeted Charlie, who was clearly already fed up with the whole situation. I went inside and was flatly told no prescription had been sent. Last year, on March 10, we lost our beloved colleague Sarah Whiteley. Sarah was a fantastic journalist; she was Metro's parenting columnist and a valued member of our first-person and opinion desk. Sarah died aged 39 from SUDEP - sudden unexpected death in epilepsy. It is thought that every year around 1,000 people die from causes related to epilepsy. With support from Sarah's family, Metro is fundraising for two very important charities: SUDEP Action and Epilepsy Action. Sarah was so incredible at helping other people share their experiences; she was a born storyteller and we hope to do her proud and raise money in her memory. Charlie ended up calling 111 a further two times – around 11:30 and midday – and even had the 111 handler talk directly to the pharmacist, but they eventually told us there was probably 'some sort of supply issue' and that a clinician would need to call us back to see what they could do. By this point, Charlie was stressed and frightened. Desperate for an alternative to continuing a fruitless search, we went to Charlie's girlfriend's flat while she was away in Manchester that weekend to see if she had any spare medication. We found two expired 6mg pills, but Charlie's dosage had since increased to 8mg. He decided to try to make them last by taking one each night until he could get to a pharmacy when they opened again on Monday. Charlie just wanted to go home to relax and calm down, even though I insisted that he should stay with us or I was happy to stay with him. That's when we drove him home and I hugged him for the last time. I actually spoke to him a few hours later after I called to check in on him. He told me that the London Ambulance Service had come back to him – a 'comfort' caller from 111, not a doctor – but nothing came of it so he was just unwinding by watching football and ordering a takeaway. The next morning, I messaged and called him but there was no reply. I immediately knew something bad had happened. By 1pm, Richard and I made our way to Charlie's flat but there was no reply to our knocks on the door, so we called the police. Once they arrived, they went inside and initially wouldn't let us follow them. When we eventually got in, we saw Charlie lifeless on the floor next to the sofa, with his uneaten takeaway on the coffee table. I actually recall a moment where I thought I saw his eyelashes flickering, so I shouted for the police to call an ambulance, but they assured me they had checked and Charlie was dead. The flickering was caused by a breeze from the open window. I ended up just lying on the floor and holding him, crying. SUDEP Action provide key services for those who have been affected by epilepsy and SUDEP. They offer free bereavement support to those who have lost a loved one to SUDEP, counselling and assist grieving families during the inquest process. SUDEP Action is passionate about providing information about SUDEP to help reduce risk to those living with epilepsy, as well as driving research to prevent future deaths. You can donate to SUDEP Action here It was the worst day of my life. When Charlie's body was released, we had a funeral for him. The church was filled with an outpouring of grief and love. In the ensuing months, we pushed for an inquest to identify exactly what went wrong. I even gave evidence and said that the Superdrug pharmacist 'wasted' my son's last day on earth, which I still stand by. Heartbreakingly, we also heard recordings of conversations Charlie and I had with NHS 111 where he pleaded with handlers: 'It's an emergency, do you understand?' The inquest concluded in February this year and the coroner highlighted 'a significant number of failures'. Notably that the GP didn't escalate the emergency prescription, that the pharmacist didn't communicate that he was actually locked out of his system so couldn't complete the 111 request, and that he only had two of the three drugs that Charlie needed. The biggest thing I was shocked to learn throughout this whole process is that certain medications can be requested in emergencies without a prescription – so long as you can prove you need it and you've previously been prescribed it. Charlie could've done that and then received five days of medication to tide him over – but not once was this mentioned to us on either day. Charlie could've been saved. If my son hadn't been failed by so many people, he'd be sitting with me now watching the tennis. This is why – with the help of SUDEP Action – I have created the Charlie Card (Get your Charlie Card from info@ which is an information card you can take to a pharmacist that quotes the Human Medicines Regulations Act 2012 in order to help get emergency medicines. More Trending And we're taking our fight to Downing Street now because we want Wes Streeting to make this knowledge more readily available. I want people to understand that Charlie's death was preventable. My loving and funny son could still be here if we knew this information. View More » As told to James Besanvalle Do you have a story you'd like to share? Get in touch by emailing Share your views in the comments below. MORE: I've worked with a lot of celebrities – Gregg Wallace was the worst MORE: I put Momcozy's pregnancy pillow to the test to see if it could break my bad habit MORE: Black Sabbath's Back to the Beginning was monumental – but I left disappointed Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
